Our IVDR-certified XCyting FISH probes are now available in 23 countries across Europe and beyond – and the list keeps growing!

The first phase of this rollout includes the following countries: Austria, Cyprus, Estonia, Germany, Iceland and The Netherlands. More countries will be supplied over time.

The number of IVDR-certified XCyting probes has now reached an impressive total of 95.

MetaSystems Probes has received IVDR certification for our XCyting FISH probes for prenatal aneusomy testing – the XA aneusomy probes.

The IVDR is effective and our probes stay the same! A large segment of our portfolio is already IVDR-certified. Our priority is to give you a smooth transition into the IVDR era.

MetaSystems Probes has received IVDR certification for our initial 26 fluorescence in situ hybridization (FISH) probes from the notified body, BSI. Achieving this milestone was not without its challenges, and we are delighted to have accomplished IVDR certification for this probe set at an early stage.

Today, MetaSystems Probes introduces 4 new probes in the field of hematology and postnatal diagnostics: XL t(11;14) CCND1/IGH DF, XL CCND3/IGH DF, XL CUX1/EZH2/7cen, and XL DiGeorge TBX1.

Today, MetaSystems Probes introduces 4 new probes in the field of hematology and oncology. XL t(5;11) NSD1/NUP98 DF, XL ETV6 BA, XL PAX5 BA, and XL 5p15/21q22 are intended as diagnostic tools for detecting recurrent aberrations described in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM).

Today, MetaSystems Probes introduces 3 new break apart probes detecting critical rearrangements in acute lymphoblastic leukemia (ALL) and T-cell prolymphocytic leukemia (T-PLL) involving the gene loci of SPI1, CSF1R and TCL1.

Researchers led by dermatologist Raffaele Gianotti of the University of Milan and pathologist Prof. Massimo Barberis, director of the Molecular Pathology Unit at Institute of European Oncology in Milan, report evidence of early SARS-CoV-2 infection in an Italian patient.

MetaSystems Probes is proud to present our new XRNA product line! It consists of five different RNA FISH probes intended for multifaceted applications. Our XRNA SARS-CoV-2 probe can be used to detect viral RNA in cell and tissue samples, while automation and quantification can be provided by MetaSystems’ slide scanning platform Metafer. The remaining probes are designed for expression analysis of two central proteins of SARS-CoV-2 viral host-cell-entry (ACE2 and TMPRSS2), and the housekeeping gene (PGK1). Additionally, we offer an XRNA probe for RNA expression analysis of the immune checkpoint component PD-L1.

Our XRNA probes can be used for analysis of many different sample types including cellular samples from swabs, sputum, bronchoalveolar lavage and tissue sections.

MetaSystems Probes is further expanding its microdeletion portfolio and adds two new probes for the detection of Prader-Willi/Angelman and Smith-Magenis/Miller-Dieker.

Today, MetaSystems Probes, MetaSystems Hard & Software and PixelBiotech are proud to announce a new high-performance solution for RNA-based detection of SARS-CoV-2 in cell and tissue samples. Find out more...

Today, MetaSystems Probes introduces 5 new dual fusion probes detecting frequent acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) associated KMT2A rearrangements.

Today, MetaSystems Probes provides the acute myeloid leukemia (AML) FISH Guide leaflet. Based on two widely accepted risk stratification models and the ‘WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues’, this informative brochure summarizes AML associated entities, their underlying chromosomal aberrations and the appropriate MetaSystems FISH probes for detection.

Today, MetaSystems Probes expands its product portfolio introducing four new probes in the field of pathology and hematology.

MetaSystems Probes launches two new probes for the detection of CRLF2-rearrangements in the context of BCR-ABL1-like ALL.

MetaSystems is further expanding its portfolio and adds three probes for the detection of frequent microdeletion syndromes.

We are very pleased to announce two new innovations in our XCyting Locus-Specific Probes product line for Hematology and Oncology.

Fluorescence in situ hybridization has become an essential detection assay in today´s routine diagnostics. However, long hybridization times of many hours to overnight are still a restrictive factor. We have refined the production process of our FISH probes to reduce background and artefacts and to improve the signal to noise ratio, particularly in short-time hybridization. Since mid-2015, one hour hybridization on lymphocytes is an integral part of quality control for all XCyting locus-specific probes at our manufacturing facility.

MetaSystems is further expanding its portfolio and adds several new probes for hematology.

Sarcomas are representing a heterogeneous group of tumors originating from mesenchymal tissue. Around 80% develop from soft tissue, the remaining 20% from bone. Sarcomas are frequently observed in children and young adults, accounting for more than 20% of all pediatric neoplasms. Due to the diversity, more than 100 subtypes are known to date, the diagnosis of sarcomas is challenging and fluorescence in situ hybridization has become a valuable tool to analyze the molecular signature of sarcoma subtypes today.

MetaSystems is further expanding it´s portfolio in the field of pathology and hematopathology.

MetaSystems is launching the XA AneuScore III Probe Kit combining the advantages of the well-known products XA AneuScore I and XA AneuScore II.

MetaSystems is introducing two new probes, XL 2p11 IGK BA and XL 22q11 IGL BA, replacing XL IGK and XL IGL, respectively.

MetaSystems is very proud to announce the XL CBFB/MYH11 plus translocation/dual fusion probe today. Always listening to our customers, we have revitalized this product as a complement to our well proven XL CBFB break apart probe.